F. Dhermain

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. · The Lancet Oncology · 2016 · 485 citations · Full text

Neuro-oncology, Glioma, Radiation Therapy +10

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 392 citations · Full text

Catnon Trial, Treatment Strategies, Radiation Therapy +13

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 307 citations · Full text

Surgical Oncology, Health Sciences, Glioma +11

Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics

Alexandre Carré, G. Klausner, Myriam Edjlali et al. · Scientific Reports · 2020 · 251 citations · Full text

Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams

G. Noël, L. Feuvret, Valentin Calugaru et al. · Acta Oncologica · 2005 · 205 citations · Full text

Conformal Technique, Fractionated Irradiation, Proton Beams +22